ADRENOCORTICAL CARCINOMA
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Status: Active
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: EudraCT 2007-007262-38, NCI-2014-00699, NCT00777244
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients With Advanced Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
Hyperthermic Intraperitoneal Cisplatin after Surgery in Treating Patients With Adrenocortical Cancer That Has Spread throughout the Abdomen
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0114, NCI-2013-01590, P131214, NCT01833832
Pembrolizumab in Treating Patients With Advanced Adrenocortical Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-286, NCI-2016-00224, NCT02673333
BREAST CANCER
Safety and Efficacy Study of the Xoft(R) Axxent(R) eBx(TM) IORT System
Status: Active
Phase: Phase IV
Type: Treatment
Age: 40 and over
Trial IDs: CTPR-0009, NCI-2013-01601, NCT01644669
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Atorvastatin Calcium in Preventing Cardiovascular Complications in Patients With Newly Diagnosed Stage I-III Breast Cancer or Lymphoma Undergoing Anthracycline-Based Chemotherapy
Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 30 to 80
Trial IDs: 98213, NCI-2013-01760, 00024197, CCCWFU 98213, WF 98213, WFU 98213, NCT01988571
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR002, NCI-2014-01810, NCT02364557
COLON CANCER
Quercetin in Preventing Venous Thromboembolic Events in Patients With Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CDR0000577892, NCI-2015-01484, NCI-2014-01372, SINGAPORE-07-32-LGI, SINGAPORE-ICR-02, ICR-02, SINGAPORE-ASCOLT, NCT00565708
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients With Stage 0-III Colon or Rectal Cancer
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-102, NCI-2012-00575, NCT01483027
HAIRY CELL LEUKEMIA
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab Before Donor Stem Cell Transplant in Treating Patients With Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2639.00, NCI-2013-00073, 2639, NCT01865617
THYROID CANCER
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: Not specified
Trial IDs: SAL 2012-0584, NCI-2014-00167, NCT01739634
Sapanisertib in Treating Patients With Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
Genetically Modified Lymphocytes in Treating Patients With Thyroglobulin-Expressing Thyroid Cancer That Is Recurrent or Metastatic and Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0090, NCI-2015-00499, 1412-1366, 150090, 342570, 8340274, P141702, RD14-XII-05, NCT02390739
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712